To illustrate this partnership around clinical studies and patient cohorts, we can mention the ORLY-Est cohort (more than 1,100 patients, enabling research on CD4 T cell lymphopenia, immune system senescence, and complications associated with kidney transplantation), as well as the cohort of acute leukemias derived from plasmacytoid dendritic cells (BPDCN). For the development of new biological drugs, we can highlight the UCPVax study, a vaccination trial using telomerase-derived peptides in non-small cell lung cancer.
These clinical studies and cohorts are registered with an NCT number on the website clinicaltrials.gov.
The RIGHT unit and CIC-1431 jointly coordinate the Bio-Monitoring platform.

